Tonix Pharmaceuticals Initiates Phase 1 Study of TNX-1900 Intranasal Oxytocin for Migraine Treatment
Key Insights
Tonix Pharmaceuticals (search) has dosed the first participant in a Phase 1 investigator-initiated study evaluating TNX-1900, an intranasal potentiated oxytocin formulation, for migraine (search) and craniofacial pain (search) treatment.
The study will assess TNX-1900's effect on trigeminal nerve-mediated vasodilation using a novel imaging technique called Laser Speckle Contrast Imaging to measure forehead blood flow responses.
TNX-1900 works through a distinct mechanism by blocking CGRP release at the trigeminal ganglion (search) level, potentially offering advantages over existing CGRP inhibitors and triptans.
Tonix Pharmaceuticals (search) Holding Corp. has initiated dosing in a Phase 1 investigator-initiated study of TNX-1900, an intranasal potentiated oxytocin formulation designed to treat migraine (search) and craniofacial pain (search) conditions. The first participant was dosed in the study evaluating the drug's effect on trigeminal nerve-mediated vasodilation in healthy female volunteers.
The study is being conducted in collaboration with Dr. Antoinette Maassen van den Brink, Professor of Neurovascular Pharmacology at Erasmus University Medical Center, who serves as principal investigator and sponsor. The research will utilize a trigeminal neurovascular reactivity model, measuring forehead skin blood flow responses to capsaicin and electrical stimulation using Laser Speckle Contrast Imaging (LSCI).
Novel Mechanism of Action
TNX-1900 represents a distinct therapeutic approach compared to existing migraine (search) treatments. In animal studies, intranasal oxytocin has demonstrated the ability to bind to oxytocin receptors in the trigeminal ganglion (search), blocking the release of calcitonin gene-related peptide (CGRP), a potent vasodilator critically involved in migraine pathogenesis.
"While there are several CGRP inhibitors approved for the treatment of migraine (search), TNX-1900's oxytocin treatment affects a distinct pathway that could address unmet needs," said Seth Lederman, MD, Chief Executive Officer of Tonix Pharmaceuticals (search). "The results of the new study will guide future development of this potential non-opioid treatment for migraine and other craniofacial pain (search) conditions."
The mechanism differs from current CGRP-targeted therapies by blocking CGRP release rather than inhibiting CGRP receptor binding or neutralizing the peptide itself. This upstream intervention occurs specifically at the trigeminal ganglion (search) level, potentially offering selective targeting advantages.
Advanced Imaging Technology
The study employs LSCI, a newer detection method for dermal blood flow that Dr. Maassen van den Brink's team recently validated in the trigeminal neurovascular reactivity model. This technology provides real-time and higher resolution dermal blood flow measurements compared to Laser Doppler Perfusion Imaging used in earlier studies.
"Oxytocin represents a potential new therapeutic option, targeting a pathway in migraine (search) and craniofacial pain (search) that is distinct from both the triptan and CGRP inhibitor migraine treatment drug classes," said Dr. Maassen van den Brink. Previous research by her team demonstrated that both CGRP inhibitors and triptans can inhibit forehead dermal blood flow responses to capsaicin in migraineurs and healthy volunteers.
Drug Formulation and Safety Profile
TNX-1900 is formulated as a drug-device combination product utilizing an intranasal actuator device for oxytocin delivery. The formulation includes magnesium, which enhances oxytocin receptor (search) binding and provides inhibitory effects on trigeminal neurons with resultant craniofacial analgesic effects, as demonstrated in animal models.
When delivered nasally, oxytocin concentrates in the trigeminal system, resulting in targeted binding to receptors on trigeminal neurons. This targeted delivery approach results in low systemic exposure and potentially lower risk of off-target effects compared to systemic CGRP inhibition.
Intranasal oxytocin has demonstrated good tolerability in several clinical trials involving both adults and children. The compound has no recognized addiction potential, and daily dosing offers more rapid reversibility compared to monthly or quarterly dosing schedules of anti-CGRP antibodies.
Market Context and Disease Burden
Migraine (search) represents a significant global health burden, with epidemiological studies indicating that approximately 1.2 billion individuals suffer from migraines annually worldwide. In the United States, approximately 39 million Americans experience migraines, with approximately four million suffering from chronic migraines defined as 15 or more headache days per month, at least eight of which are migraines.
Migraine (search) is characterized as a neurovascular condition typically manifesting as a throbbing moderate to severe headache lasting at least four hours, often unilateral and aggravated by routine physical activity. Associated symptoms can include nausea, vomiting, visual disturbances, and sensitivity to bright light and loud noises.
Broader Development Pipeline
Beyond migraine (search) and craniofacial pain (search), TNX-1900 is being developed for multiple indications including binge eating disorder, adolescent obesity, bone health in pediatric autism, and arginine-vasopressin deficiency. Tonix also holds a license with the University of Geneva to develop TNX-1900 for insulin resistance and related conditions.
The company's broader portfolio includes TONMYA (search) (cyclobenzaprine HCl sublingual tablets), marketed as the first new fibromyalgia (search) treatment in over 15 years, and established migraine (search) products Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray).